206 related articles for article (PubMed ID: 25047051)
1. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?
Hadiji N; Previnaire JG; Benbouzid R; Robain G; Leblond C; Mieusset R; Enjalbert M; Soler JM
Spinal Cord; 2014 Sep; 52(9):701-5. PubMed ID: 25047051
[TBL] [Abstract][Full Text] [Related]
2. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
4. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
Krebs J; Pannek J
Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Wöllner J; Pannek J
Spinal Cord; 2016 Jan; 54(1):78-82. PubMed ID: 26503222
[TBL] [Abstract][Full Text] [Related]
6. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
8. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity.
Stöhrer M; Mürtz G; Kramer G; Warnack W; Primus G; Jinga V; Manu-Marin A; Calomfirescu N; Strugala G
Spinal Cord; 2013 May; 51(5):419-23. PubMed ID: 23338657
[TBL] [Abstract][Full Text] [Related]
11. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
[TBL] [Abstract][Full Text] [Related]
12. The Stockholm Spinal Cord Uro Study: 3. Urodynamic characteristics in a regional prevalence group of persons with spinal cord injury and indications for improved follow-up.
Farrelly E; Lindbo L; Seiger Å
Scand J Urol; 2021 Oct; 55(5):412-418. PubMed ID: 34279177
[TBL] [Abstract][Full Text] [Related]
13. The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study.
Finazzi-Agrò E; Topazio L; Perugia C; Lombardi G; Finita Celso M; De Nunzio C; Del Popolo G
Spinal Cord; 2013 Aug; 51(8):637-41. PubMed ID: 23689390
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
15. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study.
Vasudeva P; Prasad V; Yadav S; Kumar N; Saurav K; Prashanth YM; Tyagi V
Neurourol Urodyn; 2021 Feb; 40(2):666-671. PubMed ID: 33410559
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
Schulte-Baukloh H; Mürtz G; Heine G; Austin P; Miller K; Michael T; Strugala G; Knispel HH
J Pediatr Urol; 2012 Aug; 8(4):386-92. PubMed ID: 21907623
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic treatment of vesicoureteral reflux with non-simultaneous involuntary detrusor contraction in chronic spinal cord injury patients with neurogenic detrusor overactivity.
Vírseda MC; Salinas JC; Bolufer E; Esteban MF
Urol Int; 2014; 93(4):399-402. PubMed ID: 24642572
[TBL] [Abstract][Full Text] [Related]
20. Urodynamic Differences between Complete and Incomplete Spinal Cord Injuries with Neurogenic Detrusor Overactivity.
García Fadrique G; Gallego D; Ordaz D; Climent L
Urol Int; 2020; 104(3-4):273-276. PubMed ID: 31461727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
